Welcome to THERALPHA - Innovative Therapeutics for Pain Managment

Theralpha is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment pain. Our lead product, THA903, is designed to address acute pain by sublingual administration. We have three additional product candidates in preclinical development. We are advancing next generation pain drugs based on scientifically validated Acid Sensing Ion Channel (ASIC) pathways.

Current therapies are often inadequate, have side effects, or are under-prescribed due to the dangers of addiction. There has been a lack of clinical breakthroughs in recent years, instead of Current therapies are often inadequate or have side effects, and there has been lack of clinical breakthroughs.

Theralpha aims to develop its pipeline to address unmet medical need in pain, a significant economic burden where more than 300 million people worldwide suffer. The chronic pain market is currently valued at $30 billion and is forecast to reach more than $47 billion by 2023.

We currently have four product candidates in development.

THA904 - Black mamba venom is 'better painkiller' than morphine
New publication in Nature

December 26, 2011
Green light (Tox, manufacturing, ...) to the start of the PK – PD for THA902.
THA902 is in co-development with Flamel Technologies (NASDAQ: FLML)

December 21,2011
Subalgic started for THA903. PK will start in April.

UPCOMING PARTNERING EVENTS

Meet Theralpha at BioEurope 2012 in Hamburg

Meet Theralpha in Zermatt, Switzerland for Natural Peptides to Drugs
Professor Lazdunski will present 4-6 December http://www.np2d.com/
To contact : info@theralpha.com